Clinical Trials
13 trialsNCT07150806 2026-05-22
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04082520 2026-04-22
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
NCT04040088 2026-03-31
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
Phase EARLY_PHASE1 Active not recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04529044 2025-10-30
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT03448458 2025-07-17
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Completed
NCT06611891 2025-03-04
DOTABREAST
University Hospital, Grenoble
Phase 3 Recruiting
NCT06773624 2025-01-14
Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
European Institute of Oncology
Phase NA Recruiting
NCT03953131 2023-09-01
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03136328 2023-05-09
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan
Montefiore Medical Center
Phase 3 Completed
NCT03197012 2020-07-07
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT02359500 2017-05-03
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
Icahn School of Medicine at Mount Sinai
Phase 1 Terminated